HighCape Capital
Growth equity fund founded in 2013 that invests in and helps build innovative life sciences companies across biotechnology, medical devices, and connected health.
HighCape Capital is a growth equity fund founded in 2013 that invests in and helps build innovative life sciences companies, with a stated focus on moving businesses from early stages through to commercial maturity. Its founding vehicle, the HighCape Initial Fund, closed at $80 million in 2015 with a mandate to hold stakes in six to eight commercial-stage life sciences companies - a concentrated portfolio construction that implies meaningful per-company exposure rather than broad diversification.
The firm's investment areas span life sciences, biotechnology, medical devices and tools, and connected health. Portfolio names include Elutia and Quantum-Si, alongside other biotechnology ventures. The stated emphasis on companies transitioning from product development to commercialisation suggests a stage bias towards businesses with products in or near market, rather than pure discovery-stage science.
Operating model is hands-on and collaborative. The team combines investment and operating executives with experience founding, financing, leading, growing, and exiting life sciences businesses, and works alongside portfolio-company management teams on strategy and execution. The firm describes its purpose as creating value for portfolio companies, limited partners, and the healthcare system - a tripartite framing that reflects the sector's longer development cycles and the role of clinical and commercial evidence in value creation.